Amalgamated Bank Has $4.86 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Amalgamated Bank lowered its stake in Hologic, Inc. (NASDAQ:HOLXGet Rating) by 6.8% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 63,310 shares of the medical equipment provider’s stock after selling 4,619 shares during the period. Amalgamated Bank’s holdings in Hologic were worth $4,863,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of HOLX. Fieldpoint Private Securities LLC grew its position in shares of Hologic by 61.4% during the 1st quarter. Fieldpoint Private Securities LLC now owns 334 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 127 shares in the last quarter. Veritable L.P. grew its position in shares of Hologic by 3.2% during the 1st quarter. Veritable L.P. now owns 4,721 shares of the medical equipment provider’s stock worth $363,000 after purchasing an additional 145 shares in the last quarter. Summit Global Investments grew its position in shares of Hologic by 0.8% during the 4th quarter. Summit Global Investments now owns 20,655 shares of the medical equipment provider’s stock worth $1,581,000 after purchasing an additional 162 shares in the last quarter. Quent Capital LLC grew its position in shares of Hologic by 22.3% during the 1st quarter. Quent Capital LLC now owns 887 shares of the medical equipment provider’s stock worth $68,000 after purchasing an additional 162 shares in the last quarter. Finally, Kinneret Advisory LLC grew its position in shares of Hologic by 2.3% during the 1st quarter. Kinneret Advisory LLC now owns 7,867 shares of the medical equipment provider’s stock worth $604,000 after purchasing an additional 176 shares in the last quarter. Institutional investors and hedge funds own 85.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on HOLX. UBS Group began coverage on shares of Hologic in a research report on Wednesday, July 20th. They set a “neutral” rating and a $73.00 target price on the stock. Morgan Stanley decreased their target price on shares of Hologic from $72.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 28th. Bank of America lowered shares of Hologic from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $81.00 to $75.00 in a research report on Wednesday, July 20th. Finally, BTIG Research lowered shares of Hologic from a “buy” rating to a “neutral” rating in a research report on Monday, July 18th. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $76.71.

Hologic Stock Performance

NASDAQ HOLX opened at $64.65 on Wednesday. The firm has a market capitalization of $16.14 billion, a price-to-earnings ratio of 10.90, a P/E/G ratio of 0.76 and a beta of 1.05. The company has a current ratio of 3.91, a quick ratio of 3.32 and a debt-to-equity ratio of 0.57. The firm’s 50 day simple moving average is $69.87 and its 200 day simple moving average is $72.43. Hologic, Inc. has a 1 year low of $64.03 and a 1 year high of $80.49.

Hologic (NASDAQ:HOLXGet Rating) last issued its quarterly earnings data on Wednesday, July 27th. The medical equipment provider reported $0.95 EPS for the quarter, beating the consensus estimate of $0.69 by $0.26. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $896.71 million. Hologic had a net margin of 28.93% and a return on equity of 37.48%. The firm’s revenue was down 14.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.33 EPS. As a group, research analysts expect that Hologic, Inc. will post 5.82 earnings per share for the current fiscal year.

Hologic Company Profile

(Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

Featured Stories

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.